相关实验视频
Updated: Jun 20, 2025

04:50
An Acupoint Catgut-embedding Therapy for Treating Obesity
Published on: April 4, 2025
349
塞马格卢提德和肥胖症:超越营养和生活方式干预?
Livia Basile1, Rossella Cannarella1,2, Stefano Iuliano3
1Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy.
Minerva endocrinology
|July 19, 2024
概括
作为GLP-1受体激动剂的塞马格卢提德为非糖尿病患者管理超重的安全有效选择. 本综述探讨了其临床使用,副作用以及在肥胖治疗中中止治疗的原因.
科学领域:
- 药理学 药理学是指药理学的学科.
- 内分泌学 在内分泌学.
- 重量管理重量管理
背景情况:
- 类似葡萄糖类1受体激活剂代表了肥胖药物治疗的重大进步.
- 塞马格卢提德是该类中第二种被批准用于非糖尿病人体重管理的药物.
- 超重和肥胖是全球主要的健康问题,需要有效的药理干预措施.
研究的目的:
- 对非糖尿病患者的体重管理中塞马格卢提德的临床疗效进行审查.
- 描述安全性,包括不良事件和停止治疗的原因.
- 评估用于皮下和口服塞马格卢提德配方的现有证据.
主要方法:
- 进行了临床研究的叙述性审查.
- 在PubMed数据库中,使用关键字"semaglutide和肥胖"进行了搜索.
- 综合了关于塞马格卢提德抗肥胖作用,副作用和坚持性的相关文献.
主要成果:
- 塞马格卢提德在促进超重的非糖尿病个体减肥方面表现出有效性.
- 每周一次的皮下注射和每天一次的口服配方都显示出抗肥胖作用.
- 确定和分析了常见的副作用和患者退学原因.
结论:
- 塞马格卢提德代表了非糖尿病人群中肥胖的药理治疗的新里程碑.
- 由于其剂量和施用频率,口服塞马格卢提德可能在患者坚持治疗方面具有优势.
- 需要进一步的研究,以充分阐明口服塞马格卢提德在体重管理中的长期益处和最佳使用.
相关概念视频
Glucagon-like Receptor Agonists
312
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
312
Oral Hypoglycemic Agents: Biguanides and Glitazones
186
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
186
Dipeptidyl Peptidase 4 Inhibitors
180
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
180
Diabetes: Management and Pharmacotherapy
256
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
256
Oral Hypoglycemic Agents: Glinides
152
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
152
Antidepressant Drugs: MAOIs and Other Agents
209
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
209

